Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital
About this trial
In recent years, the goal of stopping drug therapy, also known as treatment-free remission (TFR), is emerging as one of the management goals of chronic myeloid leukemia (CML) therapy. Because there is no available data on Asian patients with CML undergoing tyrosine kinase inhibitor discontinuation (TKI), the investigators plan to recruit chronic phase CML patients with deep treatment response and good medical compliance in Taiwan to evaluate the feasibility, safety and clinical consequences of TKI discontinuation.
Eligibility criteria
Qualifiers
The participant should be an adult (age ⩾20 years) with CP-CML.
The BCR-ABL fusion should be in the form of either e13a2 or e14a2 (p210)
The participant should not have documented resistance to a 2nd-generation TKI (Nilotinib or Dasatinib)
The participant should have received ≥ 5 years of consecutive treatment with imatinib, or ≥ 4 years of consecutive treatment with a 2nd-generation TKI (Nilotinib or Dasatinib)
Disqualifiers
After evaluation, the participant is deemed to be ineligible by the investigator of this study.
The participant has no intention to be recruited into this study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov